Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Decompensated NASH-Related Cirrhosis
NCT02868164Withdrawn
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Feb 2018
- Primary completion
- Feb 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, open-label trial of allogeneic fecal microbiota in Nonalcoholic steatohepatitis (NASH) and Liver cirrhosis (LC) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Number of adverse events complication rate at 1 year. Planned start Feb 2018; status: withdrawn.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT02868164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02868164.